Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Symphogen AS

www.symphogen.com

Latest From Symphogen AS

Meek To Drive M&A At Ipsen, Building On Two Major Launches

France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.

Commercial Strategy

Biopharma Quarterly Dealmaking Statistics, Q1 2016

Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.

BioPharmaceutical Deals

Deal Watch: Big Pharmas Lead Hectic New Year Deal-Making Pace

J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.

BioPharmaceutical Deals

Ex-Baxalta Plant Gives Takeda First US Biologics Capacity

Newly independent Baxalta has decided that one its domestic manufacturing facilities is surplus to requirements and is selling a biologics plant to Takeda that will become the Japanese firm's first in-house production facility in the US.

BioPharmaceutical Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Symphogen AS
  • Senior Management
  • Martin Olin, CEO
    Jesper Bramming, CFO
    Ivan D Horak, MD, CSO & CMO
    Gayle M Mills, CBO
  • Contact Info
  • Symphogen AS
    Phone: (45) 4526 5050
    Pederstrupvej 93
    Ballerup, DK-2750
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register